Sign in
Not yet recruitingPhase 3

Blood-based treatment compared with antihistamines for long-lasting hives of unknown cause

Compares a person's own blood injections with high-dose antihistamines in adults with chronic idiopathic urticaria.

Key facts

Who runs it
Cairo University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients.
Status
Not yet recruiting
Phase
Phase 3
People taking part
40 people, planned
Started
30 Apr 2026
Expected to end
30 Nov 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Autologous whole blood therapy
  • Desloratadine
Record updated
20 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic idiopathic urticaria (long-lasting hives with no known cause) that did not improve on four-fold doses of antihistamines.

Age
18 years or older
Sex
All sexes
Disease stage
Chronic idiopathic urticaria. People with a positive or a negative autologous serum skin test (ASST) can join.
Earlier treatment
Hives must not have improved on four-fold doses of antihistamines. No systemic corticosteroid or immunosuppressive drugs in the past 6 weeks.

Main reasons for not taking part

  • Other types of chronic urticaria
  • Pregnancy or breastfeeding
  • Weak immune system
  • History of bronchial asthma
  • Taking anticoagulants (blood thinners) or non-steroidal anti-inflammatory drugs

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Chronic idiopathic urticaria patients of both sexes aging 18 years of age or older who are unresponsive to four-fold of antihistamines

Who cannot take part

  • Patients on Systemic corticosteroid or immunosuppressive drugs used in the past 6 weeks
  • Patients on non-steroidal anti-inflammatory drugs
  • History of Bronchial Asthma
  • other types of chronic urticaria
  • Pregnancy
  • Lactation
  • Immunocompromised patients
  • Patients on anticoagulants

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the efficacy of Autologous Whole Blood Therapy versus conventional treatment using fourfold dose of antihistamines in Autologus serum skin test (ASST) positive and negative Chronic Idiopathic Urticaria (CIU) patients and suggest its possible mechanism of action.

The 2 groups in the trial

  • AWBT plus antihistaminesTreatment being tested

    All patients will take desloratadine 10 mg at four-fold dose daily The AWBT test group patients will receive 8 doses of autologous whole blood therapy (AWBT) once weekly. The first dose will be 2.5ml and subsequent doses will be 5ml of venous blood, which will be drawn from any accessible vein under aseptic precautions. The blood will be re-injected immediately by deep intramuscular injection (IM) on alternate gluteal regions.

    Treatment: Autologous whole blood therapy and Desloratadine

  • antihistamines aloneExisting treatment, for comparison

    All patients will take desloratadine 10 mg at four-fold dose daily

    Treatment: Desloratadine

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Autologous Whole Blood Therapy in Autologous Serum Skin Test (ASST) Positive and Negative Chronic Idiopathic Urticaria Patients, a Clinical and Biochemical Randomized Controlled Trial.
Plain-language title
Blood-based treatment compared with antihistamines for long-lasting hives of unknown causeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
20 March 2026